Produktion: NOXXON Pharma is a clinical stage biotechnology company focusing on the development of Spiegelmers* for the treatment of inflammatory diseases and hematological disorders with a large pipeline including 3 clinical candidates in 4 Phase IIa trials Emapticap pegol (NOX-E36) for Diabetic Nephropathy - complete, Olaptesed pegol (NOX-A12) for CLL and for MM, Lexaptepid pegol (NOX-H94) for Anemia of Chronic Disease and 4 preclinical candidates for: Diabetes, Inflammation, Metastasis and Pain. All NOXXON Spiegelmers* are discovered at NOXXON's research facilities using the in-house discovery platform that NOXXON has built-up through internal investment and selective licensing of technology over the years since its foundation. NOXXON's technology group also works on improvements to the Spiegelmer technology to broaden its applicability and increase the utility of Spiegelmers as therapeutics.

Forschungsschwerpunkte: NOXXON Pharma is a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called Spiegelmers*, the chemically synthesized,non-immunogenic alternative to antibodies. The Spiegelmer platform provides the company with powerful and unique discovery capabilities, which have generated a number of additional leads under preclinical investigation. Located in Berlin, Germany, NOXXON is a mature, well-financed biotech company with a strong syndicate of international investors, and approximately 55 employees.

Services: Collaborations and partnerships are an essential part of NOXXON’s business strategy. NOXXON welcomes requests from potential partners. For more information please contact Business Development at NOXXON. NOXXON collaborates with many academic investigators worldwide.

  • Mitarbeiterzahl

  • Ausrichtungen
    • Lohnhersteller / Produzenten
    • Marketing / PR / Kommunikation
    • Therapie-Entwickler
  • Gegründet

  • Aktualisiert am